CVS Group plc (LON:CVSG)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 926.15M +4.2% |
| Revenue (ttm) | 712.80M +8.7% |
| Net Income | 17.30M +517.9% |
| EPS | 0.24 +536.5% |
| Shares Out | 66.73M |
| PE Ratio | 57.12 |
| Forward PE | 14.31 |
| Dividend | 0.09 (0.65%) |
| Ex-Dividend Date | Nov 5, 2026 |
| Volume | 806,769 |
| Open | 1,369.00 |
| Previous Close | 1,367.00 |
| Day's Range | 1,353.00 - 1,393.78 |
| 52-Week Range | 1,062.00 - 1,428.00 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 1,590.42 (+14.58%) |
| Est. Earnings | Nov 26, 2026 |
About CVS Group
CVS Group plc, together with its subsidiaries, engages in veterinary practices, online pharmacy, veterinary diagnostic, and retail businesses in the United Kingdom and Australia. It operates through the Veterinary Practices, Laboratories, and Online Retail Business segments. The company is involved in animal veterinary practices and complementary veterinary diagnostic businesses. It also operates Animed Direct, an online retail business that sells prescription and non-prescription medicines, health supplements, pet foods, and pet accessories; p... [Read more]
Financial Performance
In fiscal year 2026, CVS Group's revenue was 712.80 million, an increase of 5.88% compared to the previous year's 673.20 million. Earnings were 17.30 million, a decrease of -67.23%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CVSG stock is "Buy." The 12-month stock price target is 1,590p, which is an increase of 14.58% from the latest price.
News
CVS Group price target lowered to 1,800 GBp from 1,900 GBp at RBC Capital
RBC Capital lowered the firm’s price target on CVS Group (CVSGF) to 1,800 GBp from 1,900 GBp and keeps an Outperform rating on the shares.
CVS Group initiated with a Hold at Stifel
Stifel initiated coverage of CVS Group (CVSGF) with a Hold rating and 1,300 GBp price target
CVS Group Earnings Call Transcript: H2 2026
Revenue grew 5.9% to £712.8m and adjusted EBITDA rose 5.1% to £141.5m, with all divisions contributing despite UK market softness. Strategic acquisitions continued in Australia and the UK, and regulatory clarity was achieved post-CMA. Outlook remains positive with stable RDEC income and focus on client engagement.
CVS Group Slides: H2 2026
CVS Group has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 24, 2026.
CVS Group Annual report: H2 2026
CVS Group has published its H2 2026 annual report on September 24, 2026.
CVS Group Annual report: H2 2026
CVS Group has published its H2 2026 annual report on September 24, 2026.
CVS Group H2 Earnings Call Highlights
CVS Group LON: CVSG reported higher revenue, adjusted EBITDA and adjusted earnings per share for the year ended June 30, 2026, while highlighting softer U.K. companion-animal demand late in the year a...
CVS Group Earnings Call Transcript: H2 2026
Revenue grew 5.9% to GBP 712.8 million and adjusted EBITDA rose 5.1% to GBP 141.5 million, with strong performance across all divisions and continued expansion in Australia. Leverage remains within target, and a GBP 50 million share buyback is underway.
CVS Group Annual report: H2 2026
CVS Group has published its H2 2026 annual report on September 24, 2026.
CVS Group Slides: H2 2026
CVS Group has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 24, 2026.
CVS Group Annual report: H2 2026
CVS Group has published its H2 2026 annual report on September 24, 2026.
CVS Group upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Sharanya Gajapathy upgraded CVS Group (CVSGF) to Overweight from Equal Weight with a price target of 1,630 GBp, up from 1,380 GBp. The firm cites “visibility and durability”…
CVS Group Q4 Earnings Call Highlights
CVS Group LON: CVSG said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiter...
CVS Group Earnings Call Transcript: Q4 2026
Revenue grew 5.9% to over £710 million, with stable 20% EBITDA margin and strong cash conversion. Expansion in Australia is delivering accretive returns, and a £50 million share buyback reflects confidence in future growth. Leverage remains conservative at 1.63x.
CVS Group Earnings release: Q4 2026
CVS Group released its Q4 2026 earnings on July 23, 2026, summarizing the period's financial results.
CVS Group Slides: Q4 2026
CVS Group has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 23, 2026.
CVS Group Slides: Investor presentation
CVS Group has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2026.
Converium Capital Sends Letter to CVS Group Board Highlighting Company's Undervaluation and Urging £100 Million Share Buyback
MONTREAL--(BUSINESS WIRE)--Converium Capital Inc. (“Converium”), which manages funds that own shares of CVS Group plc (LSE: CVSG) (“CVS Group” or the “Company”), today announced that it has sent a let...
UK's CVS Group CEO to step down after 7 years at the helm
British veterinary services provider CVS Group said on Monday CEO Richard Fairman plans to retire after seven years in the role.
CVS Group initiated with an Equal Weight at Barclays
Barclays initiated coverage of CVS Group (CVSGF) with an Equal Weight rating and 1,340 GBp price target The firm cites competitive dynamics in the UK merger market and the weak…
CVS Group Earnings Call Transcript: H1 2026
Revenue and EBITDA grew despite inflation and weak UK consumer confidence, with strong margin performance in Australia and ongoing disciplined M&A. Most CMA compliance measures are already in place, and further margin improvement is expected as cost pressures ease.
CVS Group Quarterly report: H1 2026
CVS Group has published its H1 2026 quarterly earnings report on February 26, 2026.
CVS Group Slides: H1 2026
CVS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
CVS Group Earnings Call Transcript: H1 2026
Revenue grew 5.8% year-over-year to GBP 356.9 million, with adjusted EBITDA up 3.9% and strong cash flow supporting continued investment. Australia now contributes 10% of revenue and 15% of EBITDA, while the group maintains leverage well below its target ceiling.
CVS Group Quarterly report: H1 2026
CVS Group has published its H1 2026 quarterly earnings report on February 26, 2026.